# US 9,750,794 B2 · Compositions and methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,750,794 B2
- Document ID: US9750794B2
- Status: Granted
- Kind: B2
- Application number: 15/067,469
- Filed: 2016-03-11
- Published: 2016-06-30
- Granted: 2017-09-05
- Earliest claimed: 2008-07-25
- Assignees: Glaxosmithkline Biologicals SA; Glaxo Group Limited
- Applicants: GlaxoSmithKline Biologicals, S.A.
- Inventors: James Brown; Pascal Mettens; Dennis Murphy
- Web page: https://patentgrep.com/patent/US9750794B2

## CPC

- A61K 39/04: Mycobacterium, e.g. Mycobacterium tuberculosis
- A61P 31/06: for tuberculosis
- A61P 37/04: Immunostimulants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/35: from Mycobacteriaceae (F)
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/55555: {Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers}
- A61K 2039/55572: {Lipopolysaccharides; Lipid A; Monophosphoryl lipid A}
- A61K 2039/55577: {Saponins; Quil A; QS21; ISCOMS}
- C07H 21/04: with deoxyribosyl as saccharide radical
- G01N 2333/35: from Mycobacteriaceae (F)
- G01N 2800/12: Pulmonary diseases
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention is directed to a polypeptide which comprises: (i) an Rv1753c protein sequence; (ii) a variant of an Rv1753c protein sequence; or (iii) an immunogenic fragment of an Rv1753c protein sequence. In other aspects the invention is directed to associated polynucleotides, fusion proteins and methods for the treatment or prevention of tuberculosis.

## Claims

### Claim 1

A pharmaceutical composition comprising:
(a) a polynucleotide encoding an Rv1753c polypeptide comprising an amino acid sequence at least 70% identical to the amino acid sequence of SEQ ID No: 1; and
(b) a pharmaceutically acceptable carrier or excipient.

### Claim 2 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the polynucleotide further comprises a heterologous nucleic acid sequence.

### Claim 3 (depends on 2)

The pharmaceutical composition according to claim 2, wherein the polynucleotide further comprising a heterologous nucleic acid sequence encodes a fusion polypeptide.

### Claim 4 (depends on 2)

The pharmaceutical composition according to claim 2, wherein the polynucleotide further comprises a vector.

### Claim 5

An immunogenic composition comprising:
(a) a polynucleotide encoding an Rv1753c polypeptide comprising an amino acid sequence at least 70% identical to the amino acid sequence of SEQ ID NO:1; and
(b) an immunostimulant.

### Claim 6 (depends on 5)

The immunogenic composition according to claim 5, wherein the polynucleotide further comprises a heterologous nucleic acid sequence.

### Claim 7 (depends on 6)

The immunogenic composition according to claim 6, wherein the polynucleotide further comprising a heterologous nucleic acid sequence encodes a fusion polypeptide.

### Claim 8 (depends on 6)

The immunogenic composition according to claim 6, wherein the polynucleotide further comprises a vector.